Syngene
- All
- News
- Videos
-
Now, 10 More Stocks Available For Derivatives Trading on NSE
Stocks Available for F&O trade on NSE: Can Fin Homes, Dixon Technologies, Hindustan Aeronautics, Indian Energy Exchange, Indiamart Intermesh, IPCA Laboratories, MCX, OFSS, Polycab India and Syngene International are added to F&O segment
-
Most Active Stocks Today: JSW Steel Falls 7%, Syngene Gains 3%
JSW Steel shares saw heavy volumes, a day after the company reported its earnings. Apollo Hospitals, HCC, and Syngene International were among other shares that saw high trading volumes today.
-
Syngene Shares Slump As Fire Breaks Out At Bengaluru Facility
Shares of Biocon, Syngene's promoter company, also came under selling pressure due to this. Biocon shares fell as much as 1.76 per cent.
-
Fire At Biocon's Research Subsidiary In Bengaluru, No Casualties Reported
A fire broke out on Monday at the premises of Syngene, the contract research subsidiary of Biocon, but there were no reports of any casualties.
-
Biocon Hits 52-Week High On Strong Q2 Earnings
Excluding exceptional item, Biocon had posted a net profit of Rs 97 crore in September quarter of the previous year.
-
Syngene Posts 54% Rise In Q2 Profit
The company announced acquisition of the bio-informatics services of Strand Life Sciences along with a team of data scientists.
-
Why Syngene International Shares Are Up 9% Today
Shares of Syngene International jumped over 9 per cent on Thursday after the contract research company closed a deal with Bengaluru-based Strand Life Sciences to purchase the latter's assets related to systems biology, Heptox and pharma bioinformatics services.
-
Syngene Sets Up R&D Centre For Amgen In Bengaluru
Biocon's contract research arm Syngene International has established an integrated, multi-disciplinary drug discovery and development centre for Amgen in Bengaluru.
-
Syngene Lines Up $200 Million Capex To Boost Manufacturing
Biocon's contract research arm Syngene International has lined up $200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years.
-
Syngene Posts 28% Rise In Q1 Profit
Biocon's contract research and manufacturing arm Syngene International on Thursday reported a 28.32 per cent rise in standalone net profit at Rs 59.8 crore for the quarter ended June, 2016.
-
Syngene Posts 20% Rise In Q4 Profit
Biocon's contract research armSyngene International on Tuesday reported a 19.6 per cent rise instandalone net profit at Rs 66.5 crore for the March quarter.
-
Syngene International Shares Surge 12% on Strong Q3
Syngene International's net profit jumped 31 per cent annually to Rs 59 crore on sales of Rs 280 crore. In the year ago period it had reported a net profit of Rs 45 crore on revenues of Rs 228 crore.
-
Syngene Posts 31% Rise in Q3 Profit
Biocon's contract research arm - Syngene International - on Thursday reported a 31.25 per cent rise in net profit at Rs 58.8 crore for the third quarter of financial year 2015-16.
-
Syngene Appoints Jonathan Hunt as CEO-designate
Syngene International, research arm of Biocon, on Monday appointed Jonathan Hunt as its CEO designate.
-
Syngene Q2 Net Profit Rises 31% to Rs 52 Crore
Syngene International, research arm of Biocon, posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30.
-
Now, 10 More Stocks Available For Derivatives Trading on NSE
Stocks Available for F&O trade on NSE: Can Fin Homes, Dixon Technologies, Hindustan Aeronautics, Indian Energy Exchange, Indiamart Intermesh, IPCA Laboratories, MCX, OFSS, Polycab India and Syngene International are added to F&O segment
-
Most Active Stocks Today: JSW Steel Falls 7%, Syngene Gains 3%
JSW Steel shares saw heavy volumes, a day after the company reported its earnings. Apollo Hospitals, HCC, and Syngene International were among other shares that saw high trading volumes today.
-
Syngene Shares Slump As Fire Breaks Out At Bengaluru Facility
Shares of Biocon, Syngene's promoter company, also came under selling pressure due to this. Biocon shares fell as much as 1.76 per cent.
-
Fire At Biocon's Research Subsidiary In Bengaluru, No Casualties Reported
A fire broke out on Monday at the premises of Syngene, the contract research subsidiary of Biocon, but there were no reports of any casualties.
-
Biocon Hits 52-Week High On Strong Q2 Earnings
Excluding exceptional item, Biocon had posted a net profit of Rs 97 crore in September quarter of the previous year.
-
Syngene Posts 54% Rise In Q2 Profit
The company announced acquisition of the bio-informatics services of Strand Life Sciences along with a team of data scientists.
-
Why Syngene International Shares Are Up 9% Today
Shares of Syngene International jumped over 9 per cent on Thursday after the contract research company closed a deal with Bengaluru-based Strand Life Sciences to purchase the latter's assets related to systems biology, Heptox and pharma bioinformatics services.
-
Syngene Sets Up R&D Centre For Amgen In Bengaluru
Biocon's contract research arm Syngene International has established an integrated, multi-disciplinary drug discovery and development centre for Amgen in Bengaluru.
-
Syngene Lines Up $200 Million Capex To Boost Manufacturing
Biocon's contract research arm Syngene International has lined up $200 million (around Rs 1,342 crore) capex to bolster its manufacturing capabilities over the next three years.
-
Syngene Posts 28% Rise In Q1 Profit
Biocon's contract research and manufacturing arm Syngene International on Thursday reported a 28.32 per cent rise in standalone net profit at Rs 59.8 crore for the quarter ended June, 2016.
-
Syngene Posts 20% Rise In Q4 Profit
Biocon's contract research armSyngene International on Tuesday reported a 19.6 per cent rise instandalone net profit at Rs 66.5 crore for the March quarter.
-
Syngene International Shares Surge 12% on Strong Q3
Syngene International's net profit jumped 31 per cent annually to Rs 59 crore on sales of Rs 280 crore. In the year ago period it had reported a net profit of Rs 45 crore on revenues of Rs 228 crore.
-
Syngene Posts 31% Rise in Q3 Profit
Biocon's contract research arm - Syngene International - on Thursday reported a 31.25 per cent rise in net profit at Rs 58.8 crore for the third quarter of financial year 2015-16.
-
Syngene Appoints Jonathan Hunt as CEO-designate
Syngene International, research arm of Biocon, on Monday appointed Jonathan Hunt as its CEO designate.
-
Syngene Q2 Net Profit Rises 31% to Rs 52 Crore
Syngene International, research arm of Biocon, posted 30.69 per cent rise in its net profit at Rs 52.29 crore for the second quarter ended September 30.
